Dynavax Technologies (NASDAQ:DVAX) COO Sells $1,782,960.00 in Stock

Dynavax Technologies Corporation (NASDAQ:DVAX) COO David Novack sold 114,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the transaction, the chief operating officer owned 63,344 shares of the company’s stock, valued at $990,700.16. This represents a 64.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX traded up $0.05 during midday trading on Tuesday, reaching $15.68. The company’s stock had a trading volume of 2,447,656 shares, compared to its average volume of 4,552,970. The company has a current ratio of 7.62, a quick ratio of 6.94 and a debt-to-equity ratio of 0.41. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -42.38 and a beta of 0.89. Dynavax Technologies Corporation has a one year low of $9.20 and a one year high of $15.73. The company has a 50 day moving average price of $12.73 and a 200 day moving average price of $11.19.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%.The firm had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. On average, equities research analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hantz Financial Services Inc. increased its position in Dynavax Technologies by 236.9% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 2,710 shares during the period. LSV Asset Management bought a new stake in shares of Dynavax Technologies in the 3rd quarter worth approximately $89,000. Osaic Holdings Inc. grew its stake in shares of Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 1,226 shares during the last quarter. Callan Family Office LLC bought a new position in Dynavax Technologies in the 2nd quarter worth about $107,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in Dynavax Technologies during the 3rd quarter valued at about $109,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DVAX has been the subject of a number of research reports. Wall Street Zen upgraded Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Finally, William Blair cut Dynavax Technologies from an “outperform” rating to a “hold” rating in a report on Wednesday, December 24th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Dynavax Technologies presently has an average rating of “Hold” and an average target price of $24.33.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.